78968-26-0

Basic information

• Product Name: BUTTPARK 16\03-25
• Synonyms: BUTTPARK 16\03-25;2-AMINO-4-(1,1-DIMETHYLETHYL)-5-THIAZOLECARBOXYLIC ACID ETHYL ESTER;ethyl 4-tert-butyl-2-aminothiazole-5-carboxylate
• CAS NO: 78968-26-0
• Molecular Formula: C10H16N2O2S
• Molecular Weight: 228.31
• Mol File: 78968-26-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BUTTPARK 16\03-25(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 16\03-25(78968-26-0)
• EPA Substance Registry System: BUTTPARK 16\03-25(78968-26-0)

Safety Data

• Hazardous Substances Data: 78968-26-0(Hazardous Substances Data)

Upstream product

• 17094-34-7 ethyl pivaloylacetate 
• 81569-29-1 ethyl 2-bromo-4,4-dimethyl-3-oxopentanoate 
• 17356-08-0 thiourea 
• 29509-07-7 2-chloro-4,4-dimethyl-3-oxopentanoic acid ethyl ester 

Downstream Products

• 81569-31-5 ethyl 2-bromo-4-t-butylthiazole-5-carboxylate 
• 72850-77-2 Ethyl-2-chlor-4-t-butyl-5-thiazolcarboxylat 
• 81569-33-7 2-bromo-4-t-butylthiazole-5-carboxylic acid 

Relevant articles and documents

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES

A medicament having inhibitory activity against NF- κ B activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.